类固醇诱发的骨质疏松_第1页
类固醇诱发的骨质疏松_第2页
类固醇诱发的骨质疏松_第3页
类固醇诱发的骨质疏松_第4页
类固醇诱发的骨质疏松_第5页
已阅读5页,还剩44页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

Corticosteroid-InducedOsteoporosis2012第一页,共四十九页。编辑课件OsteoporosisSystemicskeletaldiseaseLowbonemassMicroarchitecturaldeteriorationofbonetissueIncreaseinbonefragilityandfracturesusceptibility第二页,共四十九页。编辑课件ClinicalBurdenofCIOMostcommonformofdrug-relatedosteoporosisinmenandwomenOccursatanyage,inbothgenders,acrossracesUpto50%ofpatientsonchronicsteroidtherapysustainosteoporoticfracturesand/ordeveloposteonecrosis第三页,共四十九页。编辑课件Corticosteroid-InducedOsteoporosisCommon,iatrogenicformofsecondaryosteoporosisAssociatedwithcorticosteroiduseinchronic,noninfectiousmedicalconditionsAsthma -NephroticsyndromeChroniclungdisease -TransplantationRheumatologicdisorders -etcInflammatoryboweldisease第四页,共四十九页。编辑课件Clinicalsignificant-Increasebonelossandfracture:6Mo.-Trabecular>corticalbone-7.5mgofprednisolone(equivalent)-Incidenceofosteoporosis~30-50%-Vertebralfracture30-35%,hipfracture50%-Rateofboneloss2-4%peryear-Alternatedayregimen,inhalesteroids第五页,共四十九页。编辑课件FractureRiskandDoseofCorticosteroidsRelativeriskoffracturebydosagesofcorticosteroidsofprednisolone.vanStaaTP,etal,1998.

01234562.5mg/d2.5-7.5mg/d>7.5mg/dRelativeriskoffracturecomparedwithcontrolHipfractureVertebralfracture第六页,共四十九页。编辑课件CIOinPatientsWithAsthmaRelationshipofpercentagepredictedbonedensitytodurationofcorticosteroidusein44corticosteroid-treatedasthmaticpatients.SchatzM,DudlJ,ZeigerRS,etal.AllergyProc.1993;14:341-345.Reprintedwithpermission.Percentpredictedbonedensityr=-0.39(P=0.009)Durationofcorticosteroiduse(years)12010080604024681012141618202224262830323436第七页,共四十九页。编辑课件CIOinPatientsWithRheumatoidArthritisCS=corticosteroid;therapy=7mgprednisoneequivalentperday.DensitychangemeasuredaschangeinabsoluteorZscore(differenceinstandarddeviationcomparedwithhealthyage-matchedcontrolsofthesameraceandsex)comparedtobaseline.VerhoevenAC,etal,1997.第八页,共四十九页。编辑课件*P<0.001;**P=0.002.PercentageofSLEpatients(N=97)withlowBMD,asmeasuredbyDXA.KipenY,etal,1997.CIOandSystemicLupusErythematosus******第九页,共四十九页。编辑课件PotentialFactorsCausingBoneLossinInflammatoryBowelDiseaseCorticosteroidsVitaminD/CalciumdeficiencyPoornutritionalstatusInflammationPhysicalinactivityConcurrentmedications(immunosuppressiveagents)第十页,共四十九页。编辑课件CIOandChronicObstructivePulmonaryDisease*P<0.05vs.ISUorNSU;**P<0.005vsISU.McEvoyCE,etal,1998.***第十一页,共四十九页。编辑课件PathophysiologyofCIO:OverviewBoneremodelingoccursthroughoutadulthoodOsteoporosisresultsfromanimbalancebetweenosteoclastandosteoblastactivityTwometabolicabnormalitiescontributetoincreasedboneresorptionSecondaryhyperparathyroidismduetodecreasedGIabsorptionandurinaryexcretionofcalciumAlteredgonadalfunctionanddecreasedadrenalproductionofandrogens第十二页,共四十九页。编辑课件PathophysiologyofCIO

CalciumhomeostasisGonadalhormoneInhibitboneformationIncreaseboneresorptionother第十三页,共四十九页。编辑课件Calciumhomeostasis

DecreasecalciumandphosphatefromGItracts unknownmechanismIncreaseurinarycalciumexcretion decreasecalciumreabsorptionatdistaltubulesStimulatiomPTHsecretion第十四页,共四十九页。编辑课件GonadalhormoneeffectsDecreasesexhormone:direct&indirectDecreaseLHfrompituitarygland: estrogenandtestosteroneDecreasesynthesisfromadrenalglandsDecreasesexhormonebindingglobulin第十五页,共四十九页。编辑课件BoneformationandboneresorptionOsteoblast -inh.Osteoblastproliferation -decreasematrixsynthesis -increaseapoptosis -decreaseproteinsynthesis(type1collagenandnoncollagenousprotein -decreaseosteocalcin,IGF1,IGFBP3,5,insulin-likegrowthfactors,transforminggrowthfactorB,prostaglandinE第十六页,共四十九页。编辑课件Osteoclast increaseosteoclastactivity increaseapoptosisofmatureosteoclastBoneformationandboneresorption第十七页,共四十九页。编辑课件OsteoblastproliferationApoptosis OBnumberProteinsynthesis BoneformationDifferentiation

BonemassFracture RiskAndrogenOsteoclastapoptosis BoneresorptionOsteoclastformation PTH Calciumandphosphateabsorption(gutandkidney)

Glucocorticoid第十八页,共四十九页。编辑课件DiagnosisofCIO:

InitialClinicalWork-UpMedicalhistoryRiskfactorsforbonelossPhysicalexamClinicalsignsandsymptoms第十九页,共四十九页。编辑课件PatientEvaluation

HistoryDocumentationofheight,weight,musclestrength, balance,vision

DocumentationofmedicalhistoryDocumentationofmenstrualhistory,infertilityinmenFracturehistoryandFamilyhistoryoffracturesOtherriskfactorsforosteoporosis:-Lifestylesinfluences:calciumandvitaminDintake, smoking,alcoholintake,medications,preventionoffalling-Patienteducation:preventionoffalling,exerciseGeneralhealthandprognosis第二十页,共四十九页。编辑课件PatientEvaluationPhysicalexaminationEvidenceofosteoporosis:evidenceoffracture,kyphosis,lossofheight,musclestrengthandsizeGeneralphysicalfindings:assessmentofunderlyingdisorder,othermedicalconditions第二十一页,共四十九页。编辑课件PatientEvaluationCompletebloodcountanderythrocyte sedimentationrate(ESR)Serumcalcium,phosphate,creatinine,electrolyte,alkalinephosphatase,25-hydroxyvitaminD,estradiol,testosterone(male)24hr-UrinarycalciumandcreatinineBMDofspineandhipX-raysofappropriateareaslaboratory第二十二页,共四十九页。编辑课件

DiagnosticCriteria* Classification T=0to-1SD Normal T=-1to-2.5SD Osteopenia T

-2.5SD Osteoporosis T

-2.5SD+fragilityfractures Severeosteoporosis*Measuredin“Tscores,”ie,thenumberofstandarddeviationsbeloworabovethepeakbonemassinayoungadultreferencepopulationofthesamesex;SD=standarddeviation.WHOCriteriaforAssessingDiseaseSeverity第二十三页,共四十九页。编辑课件GuidelinesforBMDMeasurementBaselineBMDpriorto/within6monthsofinitiatingtherapyAntero-posteriormeasurementoflumbarspineandfemoralneckFollow-upat6and12months,annuallythereafteruntilbonemassstabilizesMeasuringhipalonemaymissmorerapidlossinspine第二十四页,共四十九页。编辑课件ManagementofCIO:GoalsofTreatmentReducefractureriskMaintaincurrentBMD,preventadditionalbonelossAlleviatepainassociatedwithexistingfracture(s)Maintain/increasemusclestrengthInitiatelifestylechangesasneeded第二十五页,共四十九页。编辑课件BMD,VitaminD,andCalciumAdachiJD,etal,1996.-12-10-8-6-4-206months12months18months24months30months36monthsChangeinlumbarspineBMD

frombaseline(%)VitaminD&calcium

Placebo第二十六页,共四十九页。编辑课件TreatmentHormonalreplacementtherapyCalcitoninBisphosphonatesActionInhibitboneresorptionPreventapoptosisofosteoblastsPartiallyreversebonelossPreventearlyresorptivephaseofbonelossInhibitboneresorptionMaintainorincreasebonemassPharmacologicTreatmentofCIO:Overview第二十七页,共四十九页。编辑课件PharmacologictreatmentofCIOThiazidediuretics increasecalciumabsorptionfromGItract decreaseurinarycalciumexcretionFluorides stimulateosteoblastactivityAnabolicsteroids increaseboneformation第二十八页,共四十九页。编辑课件PatientgroupPostmenopausalwomenPremenopausalwomenw/intact ovarianfunctions(ages13-50)MenRecommendationEstrogen+progestinforwomenwithintactuteriBisphosphonateorcalcitoninifHRTcontraindicated

Estrogen-containingOCs(50gestradiol)orequivalentBisphosphonateorcalcitoninif

estrogencontraindicatedTestosterone(ifserumtestosteronelevelslow)BisphosphonateorcalcitoniniftestosteronecontraindicatedHormoneReplacementTherapyintheTreatmentofCIO:ACRGuidelinesAmericanCollegeofRheumatologyTaskForceonOsteoporosisGuidelines,1996.第二十九页,共四十九页。编辑课件-0.06-0.04-0.0200.020.040.06Group1PrednisoneonlyGroup2Prednisone+ERTGroup3Control

Group4ERTonlyChangesinlumbarspineBMD(g/cm2)at1yearEstrogenReplacementTherapy

intheTreatmentofCIO*P=0.008vs.baseline;P=0.027betweengroups1and2.LukertBP,etal,1992.*第三十页,共四十九页。编辑课件TestosteroneReplacementTherapy

intheTreatmentofCIO*P=0.005vscontrol;P=0.05between-groupdifference.ReidIR,etal,1996.*-5.0-2.50.02.55.0TestosteronetherapyperiodControlperiodChangesinlumbarspineBMD(%)at1year第三十一页,共四十九页。编辑课件CyclicalEtidronateandPreventionofCorticosteroid-InducedBoneLoss*P<0.05between-groupdifference.AdachiJD,etal,1997.RouxC,etal,1998.**-4-3-2-1012LumbarspineFemoralneckTrochanterLumbarspineFemoralneckTrochanterChangesinBMDfrombaseline(%)at1yearEtidronateControl第三十二页,共四十九页。编辑课件0246Lumbarspine*FemoralneckTrochanterChangeinBMDfrombaseline(%)MenPre-menopausalwomenPost-menopausalwomenEtidronate:PooledResultsfrom

ThreeRandomizedTrials*P<0.05between-groupdifference.RouxC,etal,1998.第三十三页,共四十九页。编辑课件EfficacyofPamidronateinthe

PreventionofBoneLossBoutsenY,etal,1997.-6-4-202466months12months6months12monthsChangesinBMDfrombaseline(%)Pamidronate+calciumCalciumonly第三十四页,共四十九页。编辑课件EfficacyofAlendronateinIncreasingBMD*P<0.001vs.control;**P<0.01vs.control;†P<0.001vs.baseline,‡P<0.01vs.baseline;SaagKG,etal,1998.-1.5-0.50.51.52.53.5LumbarspineFemoralneckTrochanterTotalbodyChangeinBMDfrombaseline(%)at48weeksControlAlendronate5mgAlendronate10mg*†*†*‡*‡‡**‡*†**†第三十五页,共四十九页。编辑课件EfficacyofAlendronate:TwoYearsFollow-Up*P<0.001vs.control;**P<0.01vs.control;†P<0.05vs.control.SaagKG,etal,1998.******††-4-3-2-101234LumbarspineFemoralneckTrochanterChangeinBMDfrombaseline(%)ControlAlendronate10mgAlendronate5mgAlendronate2.5mgyear1,10mgyear2第三十六页,共四十九页。编辑课件EffectofRisedronateonBMDinPatientsInitiatingCorticosteroidTherapy*P<0.05vscontrol.CohenS,etal,1998.******-4.0-2.00.02.04.0LumbarspineFemoralneckTrochanterChangeinBMDfrombaseline(%)at12monthsControlRisedronate2.5mgRisedronate5mg第三十七页,共四十九页。编辑课件EffectofRisedronateonBMDinPatientsonLong-TermCorticosteroidTherapy*P<0.05vs.control.DevogelaerJP,etal,1998.****-3.0-2.0-1.00.01.02.03.0LumbarspineFemoralneckTrochanterChangeinBMDfrombaseline(%)at12monthsControlRisedronate2.5mgRisedronate5mg第三十八页,共四十九页。编辑课件05101520PooledcontrolpatientsPooledrisedronatepatientsPatientswithvertebralfractures(%)EffectofRisedronateonVertebralFractureRatesPooledvertebralfractureratesfrom518patientsonsteroidtherapy.*P=0.016vs.control.ReidD,etal,1998.*第三十九页,共四十九页。编辑课件

Treatment Numberof Changeinlumbar

pooledtrials spineBMD(%)*

VitaminD 18 +1.96Calcitonin 11 +2.11 Bisphosphonates 18 +5.31†BisphosphonatesintheManagementofCIO:AMeta-Analysis*Comparedwithnotreatmentorwithcalciumalone†P=0.0001comparedwithcalcitoninorvitaminD第四十页,共四十九页。编辑课件Glucocorticoidtherapyevaluation

Plan-atstartofglucocorticoidtherapy 1.Minimizeglucocorticoiddose

2.Usealternatedaytherapy,topicalsteroidor bonesparingsteroidifpossible

3.Prescribeexercise(weightbaring),physicaltherapy, preventfalling4.Avoidsmokingandexcessalcohol5.Assureadequatecalciumintake6.Addsupplementcalciumupto1000-15000mgcalcium/day7.Addmultivitamincontaining400-800IUvitaminD8.BMDmeasurementofthespineandhip:ifT-scorelower than–1SDstartHRTandifmorethan–1SDstartHRT onlyinpostmenopausalwoman第四十一页,共四十九页。编辑课件GlucocorticoidtherapyevaluationReassessmentat2-3mo1.Reviewglucocorticoidtherapy:attempttodecreaseordiscontinue2.Assessexerciseandcalciumintake3.Measureserumcalcium,24hrurinarycalciumifmorethan4mg/kg/dusehydrochlorothiazide25-50mgtwicedaily

Reassessmentat6mo

1.Reviewglucocorticoidtherapyandminimize2.Assessexerciseandcalciumintake3.Repeatserumcalciumand24hrurinarycalciummeasurement4.Altercalcium/vitaminD/thiazidetherapyifnecessary5.Ifpateintistocontinueglucocorticoid,considertorepeatBMD6.ConsiderHRT/bisphosphonate/calcitonin第四十二页,共四十九页。编辑课件Glucocorticoidtherapyevaluation

Reassessmentat1yr

1.Reviewglucocorticoidtherapyandminimize2.Assessexerciseandcalciumintake3.Repeatserumcalciumand24hrurinarycalciummeasurement4.BMDmeasurement(spineandhip)5.Altercalcium/vitaminD/thiazidetherapyifnecessary6.Alterfurtherthereapyifbonelossifcontinues

Reassessmentthereafterifglucocorticoidscontinue1.Repeatannualassessmentasabove2.Changetherapyasneeded3.Considernewerdrugsastheybecomeavailable第四十三页,共四十九页。编辑课件ACRTaskForceonOsteoporosis:

InitiatingLong-TermCorticosteroidTherapyInitialhistory&physical,lab/DXAmeasurementsCalcium/vitaminDsupplementationPatienteducationTscore<-1InitiateHRT;bisphosphonatesorcalcitoninifHRTcontraindicatedTscore>-1MonitorregularlyOnemonthfollow-up:Obtain24hurinetomeasurecalciumIf>300mg/d:addthiazidediureticAdjustdosageofcalciumandvitaminDsupplementation6-12monthsfollow-up:RepeatBMDDecrease>5%:change/addmedicationIncrease,nochange,ordecrease<5%:nochangeintherapyAmericanCollegeofRheumatologyTaskForceonOsteoporosisGuidelines,1996.第四十四页,共四十九页。编辑课件

Anticipatedtherapywithglucocorticoid

Atraumaticfractures

Yes No

Calcium1500mg/dayyesMeasurementofbonemineraldensityVitaminD400-800IU/day Lowerthan2SDbelowthemeanforExercise>5%youngadultsorLowerthan1SDbelowtheScreenforhypogonadismbonelossmeanforaged-matchcontrols NoIfhypogonadismpresent:

Calcium1000mg/dayAddhormonereplacementwith VitaminD400-800IU/dayEstrogeninwomanandtestosteroneinmenExerciseCheckBMDinoneyear:addanti-resorpt

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论